Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 April;61(2) > Minerva Cardioangiologica 2013 April;61(2):99-123

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

  INTERVENTIONAL INNOVATION NOVEL THERAPIES AND THE BEST NEW DEVICE CONCEPT FOR 2013


Minerva Cardioangiologica 2013 April;61(2):99-123

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

DES the year in review: controversies

Garg S. 1, 2, Bourantas C. 3, Serruys P. W. 3

1 Department of Cardiology East Lancashire NHS Trust Blackburn, Lancashire, UK; 2 School of Postgraduate Medicine and Dental Education University of Central Lancashire Preston, Lancashire, UK; 3 Department of Interventional Cardiology Thoraxcentre, Erasmus MC, Rotterdam, The Netherlands


PDF  


Drug-eluting stents (DES) have transformed interventional cardiology over the past decade. Whilst their efficacy has rarely been called into question, there have been concerns over the safety of the early devices, which has prompted the development of new coronary stents. Many of these new devices have entered clinical practice, however questions remain as to whether they offer the improvements in clinical outcomes that were originally anticipated. In addition, there is a debate whether the reported high efficacy of these devices enables percutaneous coronary intervention (PCI) to be performed in patient and lesion sub-groups previous entirely the domain of the cardiac surgeon. This review paper addresses these outstanding questions.

top of page

Publication History

Cite this article as

Corresponding author e-mail

scotgarg@hotmail.com